Validated against data from five in vivo studies mostly on breast tumor, the model was used to visualize spatial distributions of tumor stromal and vascular components during mono‐ and combination therapies and predicted a therapeutic window for optimal treatment efficacy for combination of anti‐VEGF and immunotherapies. The gene discussed is VEGFA; the disease is neoplasm.